SomnoMed Plans to Absorb Immediate Costs from US Tariff Changes

MT Newswires Live
04/07

SomnoMed (ASX:SOM) said it will absorb the immediate costs from new US tariffs in the immediate term, according to a Monday filing with the Australian bourse.

The company, which manufactures its products in the Philippines, is assessing the evolving impact of the tariffs, the filing said.

SomnoMed reaffirmed its fiscal year revenue guidance of about AU$105 million, with earnings before interest, taxes, depreciation, and amortization expected in the range of AU$7 million to AU$9 million, the filing added.

Shares of the company fell 19% at market close.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10